Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Items 501–600 of 1,000
Impact of induced pluripotent stem cells on the study of central nervous system disease
Cundiff, P. E., & Anderson, S. A. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.01.008 · Cited by 37
Human dermal fibroblasts in psychiatry research
Kalman, J. L., Garbett, K. A., Janka, Z., & Mirnics, K. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.067 · Cited by 48
“, 2008), spinal muscular atrophy (Ebert et al., 2009), Alzheimer’s disease (Israel et al.”
BackgroundAnnual Research Review: The promise of stem cell research for neuropsychiatric disorders
Vaccarino, F. M., Urban, A. E., Stevens, H. E., Szekely, A. M., Abyzov, A. S., Grigorenko, E. L., Gerstein, M., & Weissman, S. M. (2011) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02348.x · Cited by 41
“With this technique, iPSCs have been used to improve our understanding of the degenerative processes involved in spinal muscular atrophy (SMA), a disorder of lower motor neurons (Ebert et al., 2009).”
The Specification of Telencephalic Glutamatergic Neurons from Human Pluripotent Stem Cells
Boisvert, E. M., Denton, K., Lei, L., & Li, X.-J. (2013) · Journal of Visualized Experiments · doi:10.3791/50321 · Cited by 36
Wong, G. K. Y., & Chiu, A. T. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.07.005 · Cited by 39
Modelling familial dysautonomia in human induced pluripotent stem cells
Lee, G., & Studer, L. (2011) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0026 · Cited by 42
Vazquez‐Arango, P., Vowles, J., Browne, C., Hartfield, E. M., Fernandes, H. J. R., Mandefro, B., Sareen, D., James, W., Wade‐Martins, R., Cowley, S. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw711 · Cited by 40
Combining Induced Pluripotent Stem Cells and Genome Editing Technologies for Clinical Applications
Chang, C.-Y., Ting, H.-C., Su, H., & Jeng, J. (2018) · Cell Transplantation · doi:10.1177/0963689718754560 · Cited by 41
Sułkowski, M., Konieczny, P. S., Chlebanowska, P., & Majka, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010197 · Cited by 37
Potential application of cell reprogramming techniques for cancer research
Saito, S., Lin, Y., Nakamura, Y., Eckner, R., Wuputra, K., Kuo, K., Lin, C., & Yokoyama, K. K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2924-7 · Cited by 40
Use of Stem Cell Extracellular Vesicles as a “Holistic” Approach to CNS Repair
Branscome, H., Paul, S., Yin, D., El‐Hage, N., Agbottah, E. T., Zadeh, M. A., Liotta, L. A., & Kashanchi, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00455 · Cited by 38
Easley, C. A., Miki, T., Castro, C. A., Ozolek, J. A., Minervini, C. F., Ben‐Yehudah, A., & Schatten, G. P. (2012) · Cellular Reprogramming · doi:10.1089/cell.2011.0106 · Cited by 40
“, 2007), malignant, and degenerative diseases (Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009).”
BackgroundThe Use of Induced Pluripotent Stem Cells for the Study and Treatment of Liver Diseases
Hansel, M. C., Davila, J. C., Vosough, M., Gramignoli, R., Skvorak, K. J., Dorko, K., Marongiu, F., Blake, W. L., & Strom, S. C. (2016) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx1413s67 · Cited by 43
“…of Lesch-Nyhan syndrome Kazuki et al. (2010) Mouse and human Muscular dystrophy Soldner et al. (2009) Human Parkinson’s disease (transgene-free) Ebert et al. (2009) Human Spinal muscular atrophy Lee et al. (2009) Human Familial dysautonomia Meng et al. (2010) Mouse Lysosomal storage…”
BackgroundDarras, B. T., Markowitz, J. A., Monani, U. R., & Vivo, D. C. D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417044-5.00008-1 · Cited by 48
Converting Human Pluripotent Stem Cells to Neural Tissue and Neurons to Model Neurodegeneration
Chambers, S. M., Mica, Y., Studer, L., & Tomishima, M. J. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-328-8_6 · Cited by 37
Luo, Y., Fan, Y., Zhou, B., Xu, Z., Chen, Y., & Sun, X. (2012) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.226.151 · Cited by 45
“…has mainly focused on patients diagnosed with ‘patient-specific’ diseases, such as Amyotrophic Lateral Sclerosis (ALS), Spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD) and Parkinson Disease (PD) (Dimos et al. 2008; Ebert et al. 2009; Soldner et al. 2009; Kazuki et al. 2010).”
BackgroundPatient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery
Tang, S., Xie, M., Cao, N., & Ding, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00789 · Cited by 40
Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello Syndrome
Rooney, G. E., Goodwin, A. F., Depeille, P., Sharir, A., Schofield, C. M., Yeh, E., Roose, J. P., Klein, O. D., Rauen, K. A., Weiss, L. A., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-15.2016 · Cited by 35
“…cells have been successfully used to identify functional cellular and biochemical phenotypes linked to disease pathology in spinal muscular atrophy (Ebert et al., 2009), familial dysautonomia (Lee et al., 2009), Rett syndrome (Marchetto et al., 2010), schizophrenia (Brennand et al., 2011), and…”
BackgroundVizlin‐Hodzic, D., Zhai, Q., Illes, S., Södersten, K., Truvé, K., Parris, T. Z., Sobhan, P. K., Salmela, S., Kosalai, S. T., Kanduri, C., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.284 · Cited by 37
Shafa, M., Yang, F., Fellner, T., Rao, M. S., & Baghbaderani, B. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00069 · Cited by 36
Toyohara, T., Roudnicky, F., Florido, M. H. C., Nakano, T., Yu, H., Katsuki, S., Lee, M., Meissner, T. B., Friesen, M., Davidow, L. S., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.04.018 · Cited by 37
Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery
Nsair, A., & MacLellan, W. R. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.01.013 · Cited by 35
Alternative Sources of Pluripotent Stem Cells: Ethical and Scientific Issues Revisited
Condic, M. L., & Rao, M. S. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0482 · Cited by 46
“Since then, additional iPSC lines have been generated from patients with spinal muscular dystrophy [69], Parkinson’s disease [43], Rett syndrome [70], and type I diabetes [71].”
Human Pluripotent Stem Cells: Applications and Challenges in Neurological Diseases
Hibaoui, Y., & Féki, A. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00267 · Cited by 36
“One year after the first reprogramming of human fibroblasts into hiPSCs (Takahashi et al., 2007; Ebert et al., 2009), Daley’s group reported the generation of several hiPSCs from patients affected by Mendelian or complex genetic disorders including the neurological diseases Gaucher’s disease, Parkinson’s disease (PD),…”
BackgroundInfluentialTransformation of Human Mesenchymal Cells and Skin Fibroblasts into Hematopoietic Cells
Harris, D., Hazan‐Halevy, I., Coombes, K. R., Bueso-Ramos, C., Liu, J., Liu, Z., Li, P., Ravoori, M. K., Abruzzo, L. V., Han, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021250 · Cited by 40
“Somatic cell nuclear transfer (SCNT) was performed in the 1960s [8,21] and the generation of induced pluripotent stem (iPS) cells capable of forming cells of different tissues has been reported in recent years [22,23,24, 25,26,27,28,29].”
Hosokawa, Y., Toyoda, T., Fukui, K., Baden, M. Y., Funato, M., Kondo, Y., Sudo, T., Iwahashi, H., Kishida, M., Okada, C., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12727 · Cited by 37
Ohuchi, K., Funato, M., Kato, Z., Seki, J., Kawase, C., Tamai, Y., Ono, Y., Nagahara, Y., Noda, Y., Kameyama, T., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0059 · Cited by 34
Neural cell state shifts and fate loss in ageing and age-related diseases
Traxler, L., Lucciola, R., Herdy, J. R., Jones, J. R., Mertens, J., & Gage, F. H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00815-0 · Cited by 43
Use of engineered Schwann cells in peripheral neuropathy: Hopes and hazards
Lehmann, H. C., & Höke, A. (2015) · Brain Research · doi:10.1016/j.brainres.2015.10.040 · Cited by 37
“Proof of principle of this concept has already been demonstrated in patients with amyotrophic lateral sclerosis and in spinal muscle atrophy (Dimos et al., 2008; Ebert et al., 2009).”
BackgroundLi, W., Chen, S., & Li, J. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.009 · Cited by 38
Induction of pluripotency by defined factors
Tanabe, K., Takahashi, K., & Yamanaka, S. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.83 · Cited by 38
Clinical potential of human-induced pluripotent stem cells
Kumar, D., Anand, T., & Kues, W. A. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9370-9 · Cited by 38
Induced pluripotent stem cells: origins, applications, and future perspectives
Zhao, J. Y., Jiang, W., Sun, C., Hou, C., Yang, X., & Gao, J. (2013) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1300215 · Cited by 41
“…models have been established by patient-specific iPS cells include amyotrophic lateral sclerosis (Dimos et al., 2008), spinal muscular atrophy (Ebert et al., 2009), Parkinson's disease (Soldner et al., 2009), β-thalassemia (Ye L. et al., 2009), Rett syndrome (Hotta et al., 2009), adenosine…”
BackgroundPreclinical Assessment of Stem Cell Therapies for Neurological Diseases
Joers, V. L., & Emborg, M. E. (2010) · ILAR Journal · doi:10.1093/ilar.51.1.24 · Cited by 35
“2008), spinal muscular atrophy (Ebert et al. 2009), and PD (Soldner et al.”
BackgroundInduced pluripotent stem cells: paths to new medicines
Deng, W. (2010) · EMBO Reports · doi:10.1038/embor.2010.15 · Cited by 41
Modeling motor neuron disease: the matter of time
Arbab, M., Baars, S., & Geijsen, N. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.07.008 · Cited by 33
Modeling physiological and pathological human neurogenesis in the dish
Broccoli, V., Giannelli, S. G., & Mazzara, P. G. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00183 · Cited by 39
“It is interesting to point out that upon transplantation into neonatal brains, a fraction of the grafted neurons matured in the host neural tissue, gaining functional properties and synaptic connectivity, although several months of engraftment were required (Nicholas et al., 2013).”
BackgroundTherapy development in spinal muscular atrophy
Sendtner, M. (2010) · Nature Neuroscience · doi:10.1038/nn.2565 · Cited by 39
Pluripotent stem cell-based models of spinal muscular atrophy
Frattini, E., Ruggieri, M., Salani, S., Faravelli, I., Zanetta, C., Nizzardo, M., Simone, C., Magri, F., & Corti, S. P. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.12.005 · Cited by 34
“The first description of the feasibility of reprogramming SMA fibroblasts into iPSCs was given by Ebert and Svendsen's experiment (Ebert et al., 2009).”
BackgroundMethodInfluentialSpinal muscular atrophy: from tissue specificity to therapeutic strategies
Iascone, D. M., Henderson, C. E., & Lee, J. (2015) · F1000Prime Reports · doi:10.12703/p7-04 · Cited by 37
“SMA in humans is characterized by extensive loss of spinal motor neurons [41,54–56], and human induced pluripotent stem cells (iPSC)-derived motor neurons from SMA patients show an intrinsic survival deficit in vitro [57–59].”
BackgroundRecent advances of induced pluripotent stem cells application in neurodegenerative diseases
Amin, N., Tan, X., Ren, Q., Zhu, N., Botchway, B. O. A., Hu, Z., & Fang, M. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109674 · Cited by 39
Modeling autism spectrum disorders with human neurons
Beltrão-Braga, P. C. B., & Muotri, A. R. (2016) · Brain Research · doi:10.1016/j.brainres.2016.01.057 · Cited by 45
“In this study, motor neurons derived from SMA-iPSC patient had low survival compared to motor neurons derived from a non-affected family member (Ebert et al., 2009).”
Current progress and prospects of induced pluripotent stem cells
Chen, L., & Liu, L. (2009) · Science in China Series C Life Sciences · doi:10.1007/s11427-009-0092-6 · Cited by 37
The Role of NMDA Receptors in Neural Stem Cell Proliferation and Differentiation
Chakraborty, A., Murphy, S. K., & Coleman, N. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0325 · Cited by 38
“Abolishment of this sGluN1NP spliceosomal complex is often associated with the mutation in the SMN1 gene [95,96], leading to the PI3K/AKT antiapoptotic pathway activation in the neurons [97].”
Lai, J., Leman, L. J., Ku, S., Vickers, C. J., Olsen, C. A., Montero, A., Ghadiri, M. R., & Gottesfeld, J. M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.027 · Cited by 36
Human Induced Pluripotent Stem Cells As a Tool to Model a Form of Leber Congenital Amaurosis
Lustremant, C., Habeler, W., Plancheron, A., Goureau, O., Grenot, L., de la Grange, P., Audo, I. S., Nandrot, E. F., & Monville, C. (2013) · Cellular Reprogramming · doi:10.1089/cell.2012.0076 · Cited by 36
“Indeed, it has been reported that patient-specific iPSCs were generated successfully for several genetic disorders and diseases (Wu and Hochedlinger, 2011), with several groups showing disease-specific phenotypes in iPS-derived cells (Ebert et al., 2009; Lee et al., 2009; Marchetto et al., 2010).”
BackgroundAdvancements in stem cells treatment of skeletal muscle wasting
Meregalli, M., Farini, A., Sitzia, C., & Torrente, Y. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00048 · Cited by 36
“Now that embryonic tissue is no longer required to make a pluripotent cell, investigators have the ability to create tissuebased models of human disease based on cells derived from individual patients (Dimos et al., 2008; Park et al., 2008; Ebert et al., 2009; Soldner et al., 2009).”
BackgroundHuman Induced Pluripotent Stem Cells: The Past, Present, and Future
Hussein, S. M. I., Nagy, K. V., & Nagy, A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.37 · Cited by 35
Xie, P., Sun, Y. J., Ouyang, Q., Hu, L., Tan, Y., Zhou, X., Xiong, B., Zhang, Q., Ding, Y., Pan, Y., et al. (2014) · Stem Cells · doi:10.1002/stem.1558 · Cited by 34
Human induced pluripotent stem cells for monogenic disease modelling and therapy
Spitalieri, P., Talarico, V. R., Murdocca, M., Novelli, G., & Sangiuolo, F. C. (2016) · World Journal of Stem Cells · doi:10.4252/wjsc.v8.i4.118 · Cited by 38
Toli, D., Buttigieg, D., Blanchard, S., Lemonnier, T., d’Incamps, B. L., Bellouze, S., Baillat, G., Bohl, D., & Haase, G. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.011 · Cited by 35
“Second, motor neuron cell bodies tend to form large clusters which are inaccessible for analysis of cell survival (Chen et al., 2014; Dimos et al., 2008; Ebert et al., 2009; Hu and Zhang, 2009; Kiskinis et al., 2014;Maury et al., 2015;Qu et al., 2014; Sareen et al., 2013).”
BackgroundInduced neural stem cells (iNSCs) in neurodegenerative diseases
Hermann, A., & Storch, A. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1042-9 · Cited by 34
“Nevertheless, first reports promisingly show neuronal cell degeneration in various iPSC-based disease models, e.g. spinal muscular atrophy (Ebert et al. 2009), PD (Reinhardt et al. 2013), spinocerebellar atrophies (Koch et al. 2011) and Alzheimer’s disease (Koch et al. 2012).”
BackgroundThinking outside the liver: Induced pluripotent stem cells for hepatic applications
Rao, M. S., Sasikala, M., & Reddy, D. N. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i22.3385 · Cited by 36
Choline Ameliorates Disease Phenotypes in Human iPSC Models of Rett Syndrome
Chin, E., Marcy, G., Yoon, S.-I., Ma, D., Rosales, F. J., Augustine, G. J., & Goh, E. L. K. (2016) · NeuroMolecular Medicine · doi:10.1007/s12017-016-8421-y · Cited by 34
Hendriks, W. T. J., Jiang, X. R., Daheron, L. M., & Cowan, C. A. (2015) · Current Protocols in Stem Cell Biology · doi:10.1002/9780470151808.sc05b03s34 · Cited by 35
Shelley, B., Gowing, G., & Svendsen, C. N. (2014) · Journal of Visualized Experiments · doi:10.3791/51219 · Cited by 31
Self-citationCalcium signaling in pluripotent stem cells
Apáti, Á., Pászty, K., Erdei, Z., Szebényi, K., Homolya, L., & Sarkadi, B. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.038 · Cited by 36
Stem cell biology and cell transplantation therapy in the retina
Osakada, F., Hirami, Y., & Takahashi, M. (2009) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-26-297 · Cited by 31
“iPS cell technology represents a great advance in the field of regenerative medicine (Hanna et al., 2007; Dimos et al., 2008; Park et al., 2008; Ebert et al., 2009; Ye et al., 2009).”
BackgroundBrick, D. J., Nethercott, H. E., Montesano, S., Bañuelos, M. G., Stover, A. E., Schutte, S. S., O’Dowd, D. K., Hagerman, R. J., Ono, M. Y., Hessl, D. R., et al. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0073 · Cited by 33
Techno-Economic Analysis of Automated iPSC Production
Nießing, B., Kiesel, R., Herbst, L., & Schmitt, R. H. (2021) · Processes · doi:10.3390/pr9020240 · Cited by 32
Phenotypic Screens Targeting Neurodegenerative Diseases
Zhang, M., Luo, G., Zhou, Y., Wang, S., & Zhong, Z. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113499777 · Cited by 37
Das, A. K., & Pal, R. (2010) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.258 · Cited by 34
“Eminli et al. (2008) first showed that neural progenitor cells (NPCs) can give rise to iPSCs.”
BackgroundAutomated selection and harvesting of pluripotent stem cell colonies
Haupt, S., Grützner, J., Thier, M. C., Kallweit, T., Rath, B. H., Laufenberg, I., Forgber, M., Eberhardt, J., Edenhofer, F., & Brüstle, O. (2012) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1014 · Cited by 33
On the Road to iPS Cell Cardiovascular Applications
Kamp, T. J., & Lyons, G. E. (2009) · Circulation Research · doi:10.1161/circresaha.109.205740 · Cited by 34
In‐a‐dish: Induced pluripotent stem cells as a novel model for human diseases
Beltrão‐Braga, P. C. B., Pignatari, G. C., Russo, F. B., Fernandes, I. R., & Muotri, A. R. (2013) · Cytometry Part A · doi:10.1002/cyto.a.22231 · Cited by 30
“Using this strategy, they observed the low survival level of motor neurons in a patient with this disease when comparing with motor neurons derived from iPSC from a non affected relative (41).”
BackgroundYap, M. S., Nathan, K. G., Yeo, Y., Lim, L. W., Poh, C. L., Richards, M., Lim, W. L., Othman, I., & Heng, B. C. (2015) · Stem Cells International · doi:10.1155/2015/105172 · Cited by 41
“Another study demonstrated that application of valproic acid (VPA) and tobramycin in a spinal muscular atrophy (SMA) neuron model established from hiPSCs could upregulate expression of survival motor neuron (SMN) protein [74].”
BackgroundHuman-Induced Pluripotent Stem Cells: In Quest of Clinical Applications
Madonna, R. (2012) · Molecular Biotechnology · doi:10.1007/s12033-012-9504-0 · Cited by 33
“Recently, the generation of patientspecific iPS cells has been successfully established from patients with amyotrophic lateral sclerosis, spinal muscular atrophy (SMA), Parkinson disease, familial dysautonomia (FD), Fanconi anemia, adenosine deaminase deficiency, Schwachman–Bodian–Diamond syndrome, Gaucher disease, Du…”
BackgroundAlso‐Rallo, E., Alías, L., Martínez‐Hernández, R., Caselles, L., Barceló, M. J., Baiget, M., Bernal, S., & Tizzano, E. F. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.89 · Cited by 30
Osman, E. Y., Washington, C. W., Kaifer, K. A., Mazzasette, C., Patitucci, T. N., Florea, K. M., Simon, M. E., Ko, C., Ebert, A. D., & Lorson, C. L. (2016) · Molecular Therapy · doi:10.1038/mt.2016.145 · Cited by 35
Self-citationThe Protective Effects of Levetiracetam on a Human iPSCs-Derived Spinal Muscular Atrophy Model
Ando, S., Funato, M., Ohuchi, K., Inagaki, S., Sato, A., Seki, J., Kawase, C., Saito, T., Nishio, H., Nakamura, S., et al. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02814-4 · Cited by 31
Progress in the use of mesenchymal stromal cells for osteoarthritis treatment
Zhang, X., He, J., & Wang, W. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.01.008 · Cited by 38
“Cell therapy also shows considerable therapeutic prospects for spinal muscular atrophy [22], primary immunodeficiency, metabolic diseases and hemoglobin diseases [23], in addition to the aforementioned diseases.”
BackgroundiPSC Technology: Platform for Drug Discovery
Ellis, J., & Bhatia, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.22 · Cited by 31
Stem Cell Model of Spinal Muscular Atrophy
Ebert, A. D., & Svendsen, C. N. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.89 · Cited by 30
“We generated iPSCs from commercially available fibroblast samples obtained from a 3-year-old boy with type I SMA and his unaffected (WT) mother.(7) To do this, we used lentiviral vectors to stably express reproTable.”
MethodResultSelf-citationModeling axonal defects in hereditary spastic paraplegia with human pluripotent stem cells
Denton, K. R., Xu, C., Shah, H., & Li, X. J. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1416-0 · Cited by 36
“A number of studies have shown that spastin is capable of severing microtubules in vitro (Errico et al., 2002).”
Chang, C.-Y., Ting, H.-C., Liu, C.-A., Su, H.-L., Chiou, T., Harn, H., & Lin, S. (2018) · Cell Transplantation · doi:10.1177/0963689718775406 · Cited by 33
Neonatal immune-tolerance in mice does not prevent xenograft rejection
Mattis, V. B., Wakeman, D. R., Tom, C. M., Dodiya, H. B., Yeung, S. Y., Tran, A. H., Bernau, K., Ornelas, L., Sahabian, A., Reidling, J. C., et al. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.01.007 · Cited by 32
“Non-integrating iPSCs were grown as previously described (Ebert et al., 2009; The_HD_iPSC_Consortium, 2012).”
Self-citationNovel Insights into Disease Modeling Using Induced Pluripotent Stem Cells
Egashira, T., Yuasa, S., & Fukuda, K. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00960 · Cited by 32
Higuchi, T., Kawagoe, S., Otsu, M., Shimada, Y., Kobayashi, H., Hirayama, R., Eto, K., Ida, H., Ohashi, T., Nakauchi, H., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.02.012 · Cited by 29
Disease-Specific iPS Cell Models in Neuroscience
Peitz, M., Jungverdorben, J., & Brüstle, O. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313050014 · Cited by 36
A new era of disease modeling and drug discovery using induced pluripotent stem cells
Suh, W. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0871-0 · Cited by 34
García‐León, J. A., Vitórica, J., & Gutiérrez, A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0520 · Cited by 31
MacDougall, G., Brown, L. Y., Kantor, B., & Chiba‐Falek, O. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.001 · Cited by 33
Spinal Muscular Atrophy and the Antiapoptotic Role of Survival of Motor Neuron (SMN) Protein
Anderton, R. S., Meloni, B. P., Mastaglia, F. L., & Boulos, S. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8399-5 · Cited by 38
“While at present this method does not offer a therapeutic avenue, reprograming of SMA fibroblasts into human SMA motor neurons has potentially opened the door to targeted drug screening and improved SMA therapeutics [141].”
BackgroundNeurodegenerative disease-specific induced pluripotent stem cell research
Inoue, H. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.022 · Cited by 36
Yang, Y., Jiao, J., Gao, R., Le, R., Kou, X., Zhao, Y., Wang, H., Gao, S., & Wang, Y. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0137 · Cited by 35
iPS Cells in Type 1 Diabetes Research and Treatment
Maehr, R. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.1 · Cited by 30
López-González, R., & Velasco, I. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.01.007 · Cited by 32
McGivern, J. V., & Ebert, A. D. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.012 · Cited by 30
Self-citationDisease modelling using human iPSCs
Chamberlain, S. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw209 · Cited by 32
An introduction to induced pluripotent stem cells
Hanley, J., Rastegarlari, G., & Nathwani, A. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08296.x · Cited by 39
“…from amyotrophic lateral 18 ª 2010 Blackwell Publishing Ltd, British Journal of Haematology, 151, 16–24 sclerosis (Dimos et al, 2008), juvenile onset type 1 diabetes mellitus (Park, 2008), Parkinson’s disease and spinal muscular atrophy (SMA) (Dimos et al, 2008; Park, 2008; Ebert et al, 2009).”
BackgroundWahlestedt, M., Ameur, A., Moraghebi, R., Norddahl, G. L., Sten, G., Woods, N., & Bryder, D. (2014) · Stem Cells · doi:10.1002/stem.1630 · Cited by 30
Stem cells and the treatment of Parkinson's disease
Ali, F. R., Stott, S., & Barker, R. A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.017 · Cited by 29
“For example in Spinal muscular atrophy (Chang et al., 2011; Ebert et al., 2009), familial dysautonomia (Lee et al.”
Induced Pluripotent Stem Cells in Cardiovascular Medicine
Egashira, T., Yuasa, S., & Fukuda, K. (2011) · Stem Cells International · doi:10.4061/2011/348960 · Cited by 34
“Surprisingly latest research showed that abnormal gene expression in some cells differentiated from iPSCs can induce T-cell-dependent immune response in syngeneic recipients in contrast to derivatives of ESCs [83].”
ResultGeneration of Patient-Specific Induced Neuronal Cells Using a Direct Reprogramming Strategy
Wang, P., Zhang, H. L., Li, W., Sha, H., Xu, C., Yao, L., Tang, Q., Tang, H., Chen, L., & Zhu, J. (2013) · Stem Cells and Development · doi:10.1089/scd.2013.0131 · Cited by 28
“Successful reprogramming of adult fibroblasts into induced pluripotent stem (iPS) cells using defined transcription factors gives a potential approach to generate functional cells for the patient himself [1–14].”
From Single Genes to Gene Networks: High-Throughput-High-Content Screening for Neurological Disease
Jain, S., & Heutink, P. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.010 · Cited by 32
Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy
Liew, W. K. M., & Kang, P. B. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612472386 · Cited by 30
Bagher, Z., Ebrahimi‐Barough, S., Azami, M., Mirzadeh, H., Soleimani, M., Ai, J., Nourani, M. R., & Joghataei, M. T. (2015) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-015-9921-z · Cited by 28
“Furthermore, iPS cells, bonemarrow stromal cells, and hADSCs had also been differentiated into motor neurons with RA and Shh (Dimos et al. 2008; Ebert et al. 2009; Qi et al. 2010; Liqing et al. 2011; Lunn et al. 2011).”
BackgroundBiliouris, K., Gaitonde, P., Yin, W., Norris, D. A., Wang, Y., Henry, S. P., Fey, R. A., Nestorov, I. A., Schmidt, S., Rogge, M. C., et al. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12323 · Cited by 31
Harmony Lost: Cell–Cell Communication at the Neuromuscular Junction in Motor Neuron Disease
Gromova, A., & Spada, A. R. L. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.07.002 · Cited by 32
Generation of motor neurons from pluripotent stem cells
Chipman, P. H., Toma, J. S., & Rafuse, V. F. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59544-7.00015-9 · Cited by 27
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.